About Research Events Experts Newsroom Currency of Ideas
Milken Institute | Newsroom | Currency of Ideas - The spotlight on ETFs just got brighter Currency of Ideas: The spotlight on ETFs just got brighter
March 23, 2012 at 02:56 PM
The spotlight on ETFs just got brighter
  Capital Markets Financial Innovations Public Policy U.S. Economy
  Posted by
Daniel Gorfine
Daniel Gorfine
 
Last October, I posted a Currency of Ideas entry titled, "ETFs In the Spotlight," in which I highlighted a Senate hearing focused on potential risks in the growing $1 trillion trade of Exchange Traded Funds or Notes (ETFs/ETNs), including concerns with a lack of transparency, impact on market volatility, and contribution to systemic market risk. A particular concern at the hearing was that a lack of transparency about underlying positions of some complex ETFs or ETNs may pose significant risk to investors -- especially in leveraged products.

As it turns out, this concern about leveraged ETFs/ETNs was well-founded. Over the past 48 hours, the "VelocityShares Daily 2x VIX Short Term Exchange Traded Note" or "TVIX" has plummeted by more than 50%. Most alarming is that this drop is largely disconnected from movements in the underlying VIX index it is intended to track.

TVIX was created by Credit Suisse to return two-times the movement in the VIX (the Chicago Board Options Exchange Market Volatility Index), which measures the implied volatility of the S&P 500. TVIX is commonly referred to as the "fear index" or "fear gauge." When fear rises and market volatility increases, investors in TVIX expect a positive return.

So what happened to TVIX?
An ETF or ETN is best understood as an entity that derives its value from assets that it holds. In the simplest of examples, an ETF may hold a basket of stocks, which comprise the "asset" of the fund. By dividing the total asset value -- the value of the basket of stocks -- by the number of ETF shares, one can calculate the NAV, or Net Asset Value.

An ETF, however, trades real-time on exchanges, and therefore the share price of the ETF does not always precisely match the NAV per share. This disconnect creates an arbitrage opportunity where large financial institutions can receive newly issued ETF shares or redeem previously held ETF shares until the price of that ETF share eliminates the arbitrage opportunity.

As applied to TVIX, it turns out that because Credit Suisse was struggling to satisfy demand for new share issuances (for reasons not yet clear), it chose to cease all issuances entirely as of February 21st. This meant that there was no longer an arbitrage opportunity that had served as the key mechanism to keep the TVIX share price in-line with its NAV. This untenable situation where the share price was 89% above the NAV lasted for nearly a month, until yesterday when sellers realized the disconnect and began dumping TVIX stock. Having traded earlier in the week, and indeed for the better part of the past month, at or above $15/share, TVIX closed today slightly above $7/share.

What does all of this mean? First, despite language in the TVIX prospectus that cautions those who are not "knowledgeable investors" from investing in TVIX, many if not most investors were caught completely by surprise that ETFs/ETNs are fallible.

Second, the case is undoubtedly stronger now that policymakers should take some action to ensure that investors understand risks involved in certain complex ETF/ETN products.

And finally, the call from some within the industry -- to require product-label differentiation when the assets underlying a traded security are not equities, but rather are a combination of derivatives, swaps, and notes -- now appears sagely prescient.

Your Comment:






Please help protect our site from spammers, type the following number into the field below.

2 9 0 6 4  
      


Members of the press
may direct inquiries to:

Conrad Kiechel
Director of Communications
Phone: (310) 570-4668
Fax: (310) 570-4627
ckiechel@milkeninstitute.org

Skip Rimer

Executive Director of Programs and Communications
Phone: (310) 570-4654
Cell phone: (310) 739-7591
Fax: (310) 570-4627
srimer@milkeninstitute.org

 
 
About MI
 
About Us
  Careers
  Contact
  Download Annual Report
  FAQs
  Locations
  Our Team

Blog


Events
  Associates
  Conferences
  Global Conference
  State of the State
  Summits
    London 2013
    California 2013
  Forums
  Labs
  Young Leaders

Experts
Newsroom
  Latest News
  News Videos
  Press Releases

Research
  Centers
    Asia
    California
    FasterCures
    Financial Markets
    Israel Center

Initiatives

Publications
  Books
  Financial Innovations Labs
  Milken Institute Review
   Amazon Apps
   App Store
  Research Reports
  Viewpoints
  Search All Publications
Support MI
  Associates
  Donate
  Sponsorships
  Strategic Partners

Follow Us
  @Twitter
  Facebook
  YouTube
  Google+
  LinkedIn

Related Sites
  Celebration of Science
  Chairman's Corner
  Melanoma Research Alliance
  FasterCures
  Partnering For Cures

©2013 Milken Institute